September 2024—Qiagen and Myriad Genetics announced they will develop a globally distributable kit-based test for analyzing homologous recombination deficiency status. This next-generation sequencing test aims to support research into personalized medicine in multiple solid tumor types, including ovarian cancer, and is expected to enhance decentralized testing capacities once a regulated product is developed with pharmaceutical partners. The project builds on the master collaboration agreement that the companies announced in October 2023.
The test will be based on Qiagen’s QIAseq xHYB technology and Digital Insight solutions and Myriad’s proprietary, FDA-approved MyChoice CDx, a single-site PMA-approved centralized testing service for analyzing HRD in certain tumors. MyChoice CDx assesses HRD status by examining a tumor’s DNA repair capabilities, particularly focusing on BRCA1 and BRCA2 gene mutations, and calculating a genome instability score.
Qiagen will manage the development and distribution of the test outside of the United States. The IP license grants Qiagen the capability to collaborate with pharmaceutical partners to create an IVD-validated test, intended for use as a companion diagnostic outside the U.S.
Qiagen, +31 (77) 355 6600
Myriad Genetics, 888-268-6795